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Regadenoson Stress Pose a Concern
for Quantitative Rb-82 PET Imaging?
Optimization of Regadenoson PET Imaging*Albert J. Sinusas, MDA lthough regadenoson has nearly replacedother vasodilator stressors for single-photonemission computed tomography perfusion
imaging, the beneﬁts of regadenoson stress for posi-
tron emission tomography (PET) perfusion are less
clearly established, particularly in the estimation of
absolute stress ﬂow with dynamic PET imaging. In
the estimation of absolute ﬂow with dynamic PET,
the timing of radiotracer administration needs to be
carefully matched to the time and duration of coro-
nary hyperemia. In this issue of iJACC, Johnson and
Gould (1) suggest the regadenoson stress Rb-82
may underestimate ﬂow that can be achieved with
dipyridamole stress, and this underestimation is crit-
ically dependent on the timing of Rb-82 administra-
tion relative to the administration of regadenoson.SEE PAGE 438The authors performed a prospective study com-
paring the peak hyperemia achieved with dipyrida-
mole stress Rb-82 PET imaging with that of the
bolus administration of regadenoson using different
time delays between regadenoson vasodilator stress
and radiotracer infusion. Their data suggest that
the optimal timing for Rb-82 may be between 90
and 120 s after administration of regadenoson stress,
which represents a delay greater than that recom-
mended in the package insert for stress perfusion
imaging.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the Section of Cardiovascular Medicine, Yale University School of
Medicine, New Haven, Connecticut. Dr. Sinusas has received grant
support from Astellas Pharma US.COMPARISON WITH PRIOR STUDIES
In a group of control subjects without history of
ischemic heart disease or evidence of signiﬁcant cor-
onary stenosis on coronary angiography, Lieu et al.
(2) compared the effects of the bolus intravenous
administration of regadenoson (10 to 500 mg) with that
of intracoronary adenosine (18 mg) on coronary ﬂow.
They demonstrated a signiﬁcant variability with re-
gard to peak coronary ﬂow velocity as assessed with an
intracoronary Doppler-tipped guidewire following
administration of regadenoson ranging from 0.5 to
2.3 min. Regadenoson was also shown to increase peak
coronary ﬂow in a dose-dependent manner. These
investigators did appropriately withhold all other
drugs that could have potentially affected coronary
ﬂow, and still produced the observed variability in
response to regadenoson stress. These important ob-
servations with regard to the variability of the coro-
nary ﬂow response must be taken into consideration
when applying regadenoson stress in conjunction
with quantitative dynamic Rb-82 PET imaging. How
this variability in stress-induced ﬂow might impact
the diagnostic accuracy and clinical decision making
following regadenoson stress and rest Rb-82 PET
imaging is still not fully deﬁned.
Goudarzi et al. (3) performed a retrospective anal-
ysis of regadenoson and dipyridamole stress/rest
dynamic PET Rb-82 PET perfusion imaging studies in
matched populations (not the same patients) in
evaluation of absolute blood ﬂow and ﬂow reserve,
and demonstrated no difference in mean stress ﬂows
in 104 patients without perfusion defects or known
history of coronary artery disease. Cullom et al. (4)
performed a direct comparison of regadenoson and
dipyridamole pharmacological stress in combination
with Rb-82 PET perfusion imaging, demonstrating
visually equivalent perfusion defects in a small
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449number of patients, although did not evaluate abso-
lute ﬂow. These investigators administered 400 mg
of regadenoson over 10 s according to the package
insert followed by a 5-ml ﬂush, with initiation of the
Rb-82 infusion (25 s) immediately after the ﬂush,
similar to the group in the current study (1) that
received Rb-82 with the shortest delay.
Previous pre-clinical and clinical studies have
demonstrated that coronary ﬂow reserve is affected by
heart rate, arterial pressure, loading conditions, con-
tractile state, anemia and associated changes in blood
viscosity, presence of hypertrophy, and previous
myocardial injury (5). Sudden changes in heart rate can
result in signiﬁcant reductions in maximum coronary
ﬂow reserve (5). Heart rate is the major factor affecting
the diastolic duration, and the diastolic ﬁlling time is
an important determinant of coronary perfusion
pressure and ﬂow. Although differences in the changes
in heart and arterial pressure were assessed in the
study by Johnson and Gould (1), these indexes were
evaluated at relatively sparse time points considering
the variability in the hemodynamic response and the
critical time for myocardial extraction of Rb-82 rele-
vant to the estimation of absolute coronary ﬂow. In the
current study, they did observe signiﬁcant difference
in the heart rate between dipyridamole stress in the
various regimens for administration of regadenoson
relative to the infusion of Rb-82.
LIMITATIONS OF THE CURRENT STUDY
The authors have not addressed the issue of duration
of administration of regadenoson versus the timing of
a 10-s bolus of regadenoson in relation to Rb-82
administration. Anecdotal observations we initially
made in pre-clinical studies, and later, in our clinical
evaluation of methods for optimal regadenoson
administration in conjunction with perfusion imag-
ing, have demonstrated that the duration over
which regadenoson is administrated may be just as
important as the timing between a 10-s bolus
administration of regadenoson and radiotracer de-
livery. Administering regadenoson over 30 s resulted
in less dramatic acute changes in heart rate and blood
pressure, and a more uniform hyperemic response,
and clinically fewer side effects. We performed a
pre-clinical study directly evaluating the effects of
regadenoson administration over 30 s on global
hemodynamic, coronary ﬂow, regional myocardial
ﬂow assessed by microspheres, and radiotracer up-
take (6). This study demonstrated that regadenoson
administered over 30 s produced on average a stable
peak hyperemic response from 1 to 3 min following
completion of the regadenoson infusion, and similarto the hyperemic response achieved with continuous
infusion of adenosine over 4.5 min.
Could the ﬁnding of the current study be speciﬁc
for the imaging protocol and methodology applied? In
performing 2-dimensional PET imaging these in-
vestigators adjusted the delivery dose of Rb-82
depending on the age of the Rb-82 generator. How-
ever, other sites performing quantitative dynamic
Rb-82 3-dimensional (3D) PET imaging always
administer a lower standard dose of Rb-82 that can be
delivered over the entire 6-week life of the Rb-82
generator. Using this 3D imaging approach, the age
of the generator affects the duration over which the
Rb-82 dose is administered, as well as the initiation of
the delivery. Therefore, their ﬁndings may be some-
what unique to 2-dimensional Rb-82 PET imaging and
their speciﬁc method of ﬂow quantiﬁcation. Further
studies would be required to evaluate the optimal
timing and method of regadenoson administration in
conjunction with 3D dynamic Rb-82 PET imaging for
estimating maximal coronary hyperemia.
The more transient coronary hyperemia induced by
regadenoson might also potentially confound the
application of quantitative Rb-82 PET in patients with
depressed left ventricular function, because in these
patients there is a signiﬁcantly slower right ventricle
to left ventricle transit time. This delay in transit time
could affect circulating arterial blood levels of Rb-82
at the time of peak hyperemia, thereby inﬂuencing
myocardial extraction of Rb-82. Further clinical
studies would be needed to evaluate the inﬂuence of
this additional confounding variable.
CONCLUSIONS
In summary, Johnson et al. (1) have deﬁnitively
demonstrated that the current recommendations for
administration of regadenoson in conjunction with
dynamic Rb-82 PET imaging for evaluation of quan-
titative ﬂow require modiﬁcation, as they suggest,
with the critical need to adjust the timing between
regadenoson stress and radiotracer administration
and imaging. Their observations probably also have
implications for other types of PET perfusion imaging
with or without determination of absolute ﬂow.
However, further studies may be required to better
deﬁne the truly optimal approach for regadenoson
PET perfusion imaging depending on the radiotracer,
clinical conditions, and instrumentation applied.
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